Skip to main content

Table 4 Analysis of primary and secondary outcomes

From: A biopsychosocial approach to primary hypothyroidism: treatment and harms data from a randomized controlled trial

Outcome MCID (±) Difference between groups 7 weeks (NET-Placebo) Difference between groups 6 months (NET-Placebo) Time x group interaction
Mean difference (95 % CI) P-value Mean difference (95 % CI) P-value P-value
Depression 4 −0.58 (−4.62, 3.45) 0.78 −0.04 (−4.04, 3.96) 0.98 0.60
Anxiety 5 0.63 (−2.19, 3.46) 0.66 0.36 (−2.44, 3.16) 0.80 0.98
Stress 4 0.29 (−3.63, 4.21) 0.88 1.47 (−2.42, 5.35) 0.46 0.86
TSH 0.75 0.11 (−2.64, 2.88) 0.93 1.01 (−1.76, 3.77) 0.47 0.49
FT4 6.0 0.67 (−0.81, 2.15) 0.37 0.33 (−1.14, 1.80) 0.66 0.85
FT3 1.5 0.29 (−0.24, 0.83) 0.28 0.15 (−0.38, 0.68) 0.58 0.82
Physical functioning 3.5 −0.76 (−9.07, 7.56) 0.86 1.75 (−6.41, 9.91) 0.67 0.35
Role physical 3.2 4.25 (−7.31, 15.81) 0.47 4.35 (−6.93, 15.63) 0.45 0.99
Bodily pain 4.5 3.56 (−7.62, 14.73) 0.53 2.35 (−8.43, 13.13) 0.67 0.76
General health 5.7 2.11 (−8.20, 12.43) 0.69 3.35 (−6.78, 13.47) 0.52 0.28
Vitality 5.5 0.27 (−9.76, 10.30) 0.96 −0.10 (−9.84, 9.65) 0.98 0.76
Social functioning 5.0 9.05 (−4.55, 22.66) 0.19 5.58 (−7.54, 18.69) 0.40 0.65
Role emotional 3.8 2.12 (−8.72, 12.96) 0.70 1.13 (−9.36, 11.61) 0.83 0.86
Mental health 5.5 4.73 (−5.23, 14.72) 0.35 4.83 (−4.84, 14.49) 0.33 0.65
Mental component summary 3.1 4.11 (−1.58, 9.79) 0.16 0.22 (−5.25, 5.69) 0.94 0.36
Physical component summary 3.8 1.02 (−3.14, 5.18) 0.63 0.97 (−3.10, 5.03) 0.64 0.50
  1. MCID minimal clinically important difference, TSH thyroid stimulating hormone (mIU/L), FT4 free thyroxine (pmol/L), FT3 Free triiodothyronine (pmol/L)